FR2929615B1 - Composes c-aryl glycosides pour le traitement du diabete et de l'obesite. - Google Patents

Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.

Info

Publication number
FR2929615B1
FR2929615B1 FR0852185A FR0852185A FR2929615B1 FR 2929615 B1 FR2929615 B1 FR 2929615B1 FR 0852185 A FR0852185 A FR 0852185A FR 0852185 A FR0852185 A FR 0852185A FR 2929615 B1 FR2929615 B1 FR 2929615B1
Authority
FR
France
Prior art keywords
obesity
diabetes
treatment
glycoside compounds
aryl glycoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0852185A
Other languages
English (en)
Other versions
FR2929615A1 (fr
Inventor
Deliencourt Godefroy Geraldine Castelot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tfchem SARL
Original Assignee
Tfchem SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tfchem SARL filed Critical Tfchem SARL
Priority to FR0852185A priority Critical patent/FR2929615B1/fr
Priority to CA2720011A priority patent/CA2720011C/fr
Priority to US12/935,468 priority patent/US8486897B2/en
Priority to PCT/EP2009/053970 priority patent/WO2009121939A2/fr
Priority to EP09727801.4A priority patent/EP2280983B9/fr
Publication of FR2929615A1 publication Critical patent/FR2929615A1/fr
Application granted granted Critical
Publication of FR2929615B1 publication Critical patent/FR2929615B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
FR0852185A 2008-04-02 2008-04-02 Composes c-aryl glycosides pour le traitement du diabete et de l'obesite. Expired - Fee Related FR2929615B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0852185A FR2929615B1 (fr) 2008-04-02 2008-04-02 Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
CA2720011A CA2720011C (fr) 2008-04-02 2009-04-02 Composes c-aryl glycosides pour le traitement du diabete et de l'obesite
US12/935,468 US8486897B2 (en) 2008-04-02 2009-04-02 C-aryl glycoside compounds for the treatment of diabetes and obesity
PCT/EP2009/053970 WO2009121939A2 (fr) 2008-04-02 2009-04-02 Composés c-aryl glycosides pour le traitement du diabète et de l'obésité
EP09727801.4A EP2280983B9 (fr) 2008-04-02 2009-04-02 Composés c-aryl glycosides pour le traitement du diabète et de l'obésité

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0852185A FR2929615B1 (fr) 2008-04-02 2008-04-02 Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.

Publications (2)

Publication Number Publication Date
FR2929615A1 FR2929615A1 (fr) 2009-10-09
FR2929615B1 true FR2929615B1 (fr) 2010-12-17

Family

ID=39500050

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0852185A Expired - Fee Related FR2929615B1 (fr) 2008-04-02 2008-04-02 Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.

Country Status (5)

Country Link
US (1) US8486897B2 (fr)
EP (1) EP2280983B9 (fr)
CA (1) CA2720011C (fr)
FR (1) FR2929615B1 (fr)
WO (1) WO2009121939A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI523652B (zh) 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
AP3308A (en) 2011-05-26 2015-06-30 Tfchem Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
TW201418242A (zh) 2012-10-26 2014-05-16 Du Pont 作為除草劑之經取代的三唑
CA2903770C (fr) 2013-03-14 2022-07-12 Mars, Incorporated Composition de saveur contenant des glucosides a l'acide 3-hydroxy-3-methylglutarique (hmg)
RU2018147235A (ru) 2016-06-02 2020-07-10 Санофи Конъюгаты фармацевтического средства и фрагмента, способного связываться с глюкозочувствительным белком
EP3717463A1 (fr) * 2017-12-01 2020-10-07 Sanofi Nouveaux conjugués constitués d'un agent pharmaceutique et d'une fraction pouvant se lier à une protéine de détection du glucose
EP4074317A1 (fr) 2021-04-14 2022-10-19 Bayer AG Dérivés de phosphore en tant que nouveaux inhibiteurs de sos1
CN116023273A (zh) * 2023-03-29 2023-04-28 思合基因(北京)生物科技有限公司 一种新型碳糖苷及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6683056B2 (en) * 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
AR048377A1 (es) 2003-08-01 2006-04-26 Janssen Pharmaceutica Nv Benzoimidazol-, benzotriazol- y benzoimidazolona - o- glucosidos sustituidos
CN1870988A (zh) * 2003-10-30 2006-11-29 默克公司 作为抗高胆固醇血症药的2－氮杂环丁烷酮
FR2900405B1 (fr) 2006-04-27 2013-11-29 Inst Nat Sciences Appliq Nouveaux composes c-glycosides monofluores, leurs procedes de preparation et leurs applications
US8450286B2 (en) 2008-03-18 2013-05-28 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof

Also Published As

Publication number Publication date
EP2280983A2 (fr) 2011-02-09
EP2280983B9 (fr) 2021-06-09
EP2280983B1 (fr) 2013-03-13
CA2720011C (fr) 2016-07-05
WO2009121939A3 (fr) 2010-11-11
CA2720011A1 (fr) 2009-10-08
FR2929615A1 (fr) 2009-10-09
US20110034402A1 (en) 2011-02-10
WO2009121939A2 (fr) 2009-10-08
US8486897B2 (en) 2013-07-16

Similar Documents

Publication Publication Date Title
FR2929615B1 (fr) Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
IL254157B (en) 3–14–eta antibodies and their uses for the diagnosis and treatment of arthritis
EP2180896A4 (fr) Composition pour le diagnostic, la prévention ou le traitement de maladies liées à l'expression il-8 ou gro-alpha de cellules, comprenant des cellules souches mésenchymateuses ucb
CL2007000806A1 (es) Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
IL184312A0 (en) Herbal compositions for the treatment of diabetes and/or conditions associated therewith
FR2932478B1 (fr) Composes utiles pour le traitement des cancers.
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
EP2103628A4 (fr) Anticorps monoclonal anti-claudine 3, et traitement et diagnostic du cancer au moyen d'un tel anticorps
EP2212440A4 (fr) Procédés et compositions destinés au diagnostic et au traitement de l'adénocarcinome de l' sophage
EP1991218A4 (fr) Utilisation de cyclolignans dans le traitement du diabète de type 2 et comme contraceptifs
EP2041317A4 (fr) Procédés et compositions à base de micro-arn pour le diagnostic et le traitement de maladies apparentées au cancer du colon
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
EP3318562A3 (fr) Dérivés de benzylbenzène et procédés d'utilisation
EA201101189A1 (ru) Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии
WO2007007173A3 (fr) Nouveaux anticorps anti-madcam
BRPI0719849A2 (pt) Método de imunização contra os quatro sorotipos da dengue
PL2018184T3 (pl) Przeciwciało Anty-VEGF-B do stosowania w leczeniu lub profilaktyce cukrzycy typu II lub zespołu metabolicznego
FR2928832B1 (fr) Orthese de poignet, destinee au traitement du syndrome du canal carpien
SMT201500190B (it) Composizioni comprendenti un anticorpo a p2-specifico o un suo frammento per l'uso nel trattamento del diabete, intolleranza al glucosio o insulino-resistenza indotta dall'obesita'
HK1197052A1 (en) Low scale potential water treatment
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
GB0909297D0 (en) Composition for the treatment of skin conditions
FR2906468B1 (fr) Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
EP2473176A4 (fr) Composés neuroprotecteurs, compositions, procédés et trousses
FR2904756B1 (fr) Dispositif de maintien des seins pour application medicale.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20151231